This is a median for individual episodes across a trial population, so half of episodes ran longer, and it is not a forecast for any one person
Rybelsus is currently being studied for weight loss in clinical trials
9: Mari A, Stefanski A, van Raalte DH, Ma X, LaBell ES, Fan L, Lee CJ, Thomas MK, Bunck MC, Ferrannini E
Tolerability + symptom support tools (troubleshooting guide, food tolerance ladder, GI comfort plan, symptom log)
When To Call Your Clinician Versus When to Head to the Emergency Department Call your clinician promptly if symptoms last more than a few days, get worse, or stop you from doing daily tasks like working or keeping fluids down
GLP-1R agonists have been approved for the treatment of T2DM since 2005, but it was only with the approval of tirzepatide (a dual GLP-1R/GIPR agonist) in 2022 that a drug acting on GIPR was used clinically (Le Roux et al., 2023)